| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ec69b04534a2552b19d2aa4c40a43a7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-18141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-18123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10041 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-66 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-66 |
| filingDate |
2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_350f348babcda32e7efb713f84e26b79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b271b17c9caaf67d7c0c2e19d86a8dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b9496f5b113167ed84ae06ebc90baf6 |
| publicationDate |
2020-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020031136-A1 |
| titleOfInvention |
Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer |
| abstract |
The invention relates to the field of medicine and molecular biology and may be used for long-lasting therapy of cancer with adjuvant effect using SANPs-theranostics (SANPs – self assembled nano particles). A composition of self assembled nanoparticles comprising: a) a ligand of conjugation binding to membrane antigen of prostate (PSMA); b) a ligand of conjugation binding to integrin αvβ3, c) a biologically active agent; and d) nanoparticles, wherein the biologically active agent is monovalent thallium compound, preferably thallium salt. |
| priorityDate |
2018-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |